Targeting TAK1 as a non-redundant cytosolic mediator of the activation of NF-κB could represent a novel approach to modulate the intrinsic and acquired chemoresistance and make a difference in pancreatic cancer addicted to the activity of this transcription factor. The gene discussed is MAP3K7; the disease is familial pancreatic carcinoma.